Medtronic, a leading medical technology company (NYSE：MDT) in2025Asia Pacific Heart Rhythm Society (APHRS) During the scientific conference,Published itsAuroraExtravascular Implantable Cardioverter Defibrillator (EV-ICD) andOmniaSecureLatest Clinical Data on Defibrillation Leads: Two Studies Validate Breakthrough Advances in Safety, Efficacy, and Reliability of Innovative Technology.

EnlightenThe study data from the registry after approval comes from23National786Number of patients, confirmedAurora EV-ICDIn the scenario of extravascular single-device implantation, high anti-tachycardia pacing was achieved (ATP) Success rate and effective defibrillation capability. Specific data shows:

• ATPTermination of Ventricular Tachycardia (VT) Success rate reached67%, avoid44Secondary Electric Shock Incident;

• 97.8%The patients did not experience any chronic major system-related complications during the six-month follow-up period;

• System to100%Effective treatment for spontaneous fatal arrhythmia events;

• Inappropriate shock rate reduced compared to pre-market studies32%, thanks to its equipped withSmart SenseTechnology can reduce over-sensing.

• Cardiologist at Christchurch Hospital, New ZealandIan CrozierDr. emphasized in the conference: "The high consistency between real-world data and key trial results confirms the significant advantages of extravascular defibrillators in reducing unnecessary shocks and improving patient experience."

  
  

LEADRThe three-year follow-up results further reinforcedOmniaSecureClinical Value of Defibrillation Leads. The diameter of this lead is only4.7French (approximately1.6Millimeters, equivalent to the diameter of a wooden pencil's graphite), is currently the world's smallest defibrillation lead, with long-term validation of safety for right ventricular implantation and defibrillation efficacy:

• Defibrillation Success Rate at the Time of Implantation97.5%, maintained in a three-year outpatient environment95.3%；

• 96.5%No lead-related major complications occurred in the patients;

• Lead Fracture Rate and10Annual Reliability Model Prediction98.2%No breakage rate consistency;

• ATPEffective Rate75.4%，22.3%TheATPThe event was accompanied by appropriate shock delivery, with stable electrical performance.

The lead is based on MedtronicSelectSecure 3830Pacemaker lead technology upgrade, at2025Year4Monthly AcquisitionFDAApproved for right ventricular implantation, expanding the precise delivery capabilities of Medtronic's lead solutions.

Vice President of Defibrillation Solutions, Cardiac Rhythm Management Business at MedtronicTrevor CookPointed out: "ICDIt is a cornerstone technology for preventing sudden cardiac death, but patient needs vary individually.Aurora EV-ICDAs the only extravascular implant device, it providesATPAvoid intravascular procedures while treating; andOmniaSecure"Leads enhance implant safety through minimally invasive design. These innovations are reshaping the patient experience while ensuring protection against life-threatening arrhythmias."

Data from two studies were simultaneously published on Medtronic's official platform. This data release marks the mature application of extravascular defibrillation technology and ultra-minimally invasive lead design in real-world scenarios, offering safer and more personalized treatment options for millions of arrhythmia patients worldwide.